about
B cells and the humoral response in melanoma: The overlooked players of the tumor microenvironmentStem cell technologies for tissue regeneration in dentistry.Rho and Rap guanosine triphosphatase signaling in B cells and chronic lymphocytic leukemia.Anti-Folate Receptor-α IgE but not IgG Recruits Macrophages to Attack Tumors via TNFα/MCP-1 Signaling.Cuttlefish bone scaffold for tissue engineering: a novel hydrothermal transformation, chemical-physical, and biological characterization.Functionally Active Fc Mutant Antibodies Recognizing Cancer Antigens Generated Rapidly at High Yields.BRAF inhibitors: resistance and the promise of combination treatments for melanoma.Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types.In-vitro and in-vivo evidence for uncoupling of BCR internalization and signaling in chronic lymphocytic leukemia.Engineering and stable production of recombinant IgE for cancer immunotherapy and AllergoOncology.Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs).Anti-Folate Receptor Alpha-Directed Antibody Therapies Restrict the Growth of Triple-negative Breast CancerCalcium-RasGRP2-Rap1 signaling mediates CD38-induced migration of chronic lymphocytic leukemia cellsRegional Activation of Myosin II in Cancer Cells Drives Tumor Progression via a Secretory Cross-Talk with the Immune MicroenvironmentCombining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in MelanomaIn vivo safety profile of a CSPG4-directed IgE antibody in an immunocompetent rat modelIgE re-programs alternatively-activated human macrophages towards pro-inflammatory anti-tumoural statesAllergoOncology: Expression platform development and functional profiling of an anti-HER2 IgE antibody
P50
Q33632113-FC2CED35-5C52-4670-B955-976C03047A67Q37628440-BCBC9674-2EEC-42FB-BED2-27042172507AQ38163044-405D5121-447F-4A9A-913B-BE100F5D2086Q38720904-B721F107-7550-4E1E-8908-620DF95D9106Q39314119-4D465637-CCA5-404E-9073-4DB8C39B3873Q41673094-BE7933D9-32C4-49ED-8B1C-48637CF907EFQ47104481-47204344-FE4F-4F98-B70B-B93A01C95489Q47555734-794D9A8C-E8C5-4B73-841C-A8FE8AAD99FAQ49837442-0813BEB7-06C2-4589-B327-9E642A4BE7C8Q49841005-DEEC5279-BF0B-4BBF-8BBF-DEF294050293Q52704026-D051009D-2F1B-48DD-B786-4895587BB46BQ57462222-170271E8-07AE-4860-9822-2B2863AE28BCQ57909866-D9D3E11E-34A6-44DB-A91D-9276CFC36B1AQ61797822-E4FA6B3D-BD9E-4CB8-AC78-4026B82DDD1BQ64075100-F205F368-652C-40DE-887A-D78B3BBED52EQ91461311-A1DAACA1-F02A-4773-BC4B-599FB1D55187Q92907647-1D1FA012-4FB2-4443-899F-F9B6CDAD2906Q92967706-6FF38FF4-533E-47AE-A579-EC8EBF663800
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0003-3709-5739
@en
name
Silvia Mele
@ast
Silvia Mele
@en
Silvia Mele
@es
Silvia Mele
@nl
type
label
Silvia Mele
@ast
Silvia Mele
@en
Silvia Mele
@es
Silvia Mele
@nl
prefLabel
Silvia Mele
@ast
Silvia Mele
@en
Silvia Mele
@es
Silvia Mele
@nl
P106
P21
P31
P496
0000-0003-3709-5739